Publications en collaboration avec des chercheurs de Hospital del Mar (21)

2023

  1. Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA Registry

    Journal of Crohn's & colitis, Vol. 17, Núm. 1, pp. 83-91

  2. Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated with Internal Fistulizing Disease: BIOSCOPE Study from GETECCU

    American Journal of Gastroenterology, Vol. 118, Núm. 6, pp. 1036-1046

2022

  1. Corrigendum to: Re-induction With Intravenous Ustekinumab in Patients With Crohn's Disease and a Loss of Response to This Therapy

    Inflammatory bowel diseases

  2. Erratum: Re-induction with Intravenous Ustekinumab in Patients with Crohn's Disease and a Loss of Response to This Therapy (Inflammatory Bowel Diseases DOI: 10.1093/ibd/izab015)

    Inflammatory Bowel Diseases

  3. Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients

    Frontiers in Medicine, Vol. 9

  4. Re-induction With Intravenous Ustekinumab in Patients With Crohn's Disease and a Loss of Response to This Therapy

    Inflammatory bowel diseases, Vol. 28, Núm. 1, pp. 41-47

  5. Risk of Immunomediated Adverse Events and Loss of Response to Infliximab in Elderly Patients with Inflammatory Bowel Disease: A Cohort Study of the ENEIDA Registry

    Journal of Crohn's & colitis, Vol. 16, Núm. 6, pp. 946-953

2021

  1. Placental DNA methylation signatures of maternal smoking during pregnancy and potential impacts on fetal growth

    Nature Communications, Vol. 12, Núm. 1

  2. Tofacitinib in ulcerative colitis: Real-world evidence from the ENEIDA registry

    Journal of Crohn's and Colitis, Vol. 15, Núm. 1, pp. 35-42

2020

  1. Early treatment with anti-tumor necrosis factor agents improves long-term effectiveness in symptomatic stricturing Crohn’s disease

    United European Gastroenterology Journal, Vol. 8, Núm. 9, pp. 1056-1066

  2. Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients with Inflammatory Bowel Disease: Results from the Eneida Registry

    Inflammatory Bowel Diseases, Vol. 26, Núm. 4, pp. 606-616

2018

  1. DNA methylation in childhood asthma: an epigenome-wide meta-analysis

    The Lancet Respiratory Medicine, Vol. 6, Núm. 5, pp. 379-388

  2. Post-operative morbidity and mortality of a cohort of steroid refractory acute severe ulcerative colitis: Nationwide multicenter study of the GETECCU ENEIDA Registry

    American Journal of Gastroenterology, Vol. 113, Núm. 7, pp. 1009-1016

2014

  1. Risk of colectomy in patients with ulcerative colitis under thiopurine treatment

    Journal of Crohn's and Colitis, Vol. 8, Núm. 10, pp. 1287-1293

2013

  1. Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome

    Journal of Crohn's and Colitis, Vol. 7, Núm. 9, pp. 717-722

  2. Smoking does influence disease behaviour and impacts the need for therapy in Crohn′s disease in the biologic era

    Alimentary Pharmacology and Therapeutics, Vol. 38, Núm. 7, pp. 752-760

2012

  1. Effectiveness of infliximab after adalimumab failure in Crohn's disease

    World Journal of Gastroenterology, Vol. 18, Núm. 37, pp. 5219-5224

  2. Long-term durability of response to adalimumab in Crohn's disease

    Inflammatory Bowel Diseases, Vol. 18, Núm. 4, pp. 685-690

2011

  1. Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose "escalation" in patients losing response

    Journal of Clinical Gastroenterology, Vol. 45, Núm. 2, pp. 113-118

2010

  1. Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy

    Gut, Vol. 59, Núm. 10, pp. 1340-1346